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ABSTRACT Human serum albumin (HSA) has seven common fatty acid (FA) binding sites. In this study, we used the molecular
mechanicsPoisson-Boltzmannsurfaceareamethod to identify highafﬁnity FAbinding sitesonHSA in termsof binding freeenergy.
Usingmultiple HSA-FA (myristate, palmitate) complexmodels constructed bymolecular dynamics simulations, twomethodswere
performed in molecular mechanics Poisson-Boltzmann surface area, the ‘‘three-trajectory method’’ and the ‘‘single-trajectory
method’’. The former, which is less precise than the latter but may be more accurate as it includes the effects of conformational
changeuponbinding,wasused to classify highand lowafﬁnity sites.Asa result, Sites2, 4, and5were identiﬁedashighafﬁnity sites
for both FAs. The latter method, which is precise because energies are calculated from snapshots of the same trajectory for HSA-
FAcomplex,wasperformed to compare themagnitudeof binding freeenergy for these sites. Theorder ofmagnitudewas5.4.2,
identical to that of a previous publication by others. In this way, a combination of the two methods was effectively used to identify
high afﬁnity sites. This study therefore provides an insight into the quantitative identiﬁcation of high afﬁnity FAbinding sites onHSA.
INTRODUCTION
Human serum albumin (HSA) is a major protein component
of blood plasma. It serves as a transport protein for several
endogenous compounds, such as unesteriﬁed fatty acids
(FA) and bilirubin, and is also capable of binding a broad
spectrum of therapeutic agents. Drug binding to HSA can
result in a prolonged in vivo half-life. Thus, the binding
property of drugs to HSA is one of the most important factors
determining their pharmacokinetics (1).
HSA consists of 585 amino acids and has a molecular
mass of 66,500 Da. Recently, three-dimensional structures of
HSA have been obtained by x-ray crystallography (2–4). The
structure of HSA consists of three homologous domains
(domains I–III), each of which is divided into two subdo-
mains, A and B, having six and four a-helices, respectively.
For these subdomains, the positions and architecture of a
broad spectrum of drugs have been identiﬁed by x-ray
crystallography of HSA-drug complexes (5). The positions
and architecture of FA binding sites on HSA have been also
identiﬁed for these subdomains (6–9). Seven common FA
binding sites have been identiﬁed for medium and long-chain
FAs (8), and monosaturated and polyunsaturated FAs (9).
Under normal physiological conditions, HSA binds with
;0.1–2 mol of FA, per mol of protein (10). However, the
molar ratio of FA/HSA can rise up to 6 during fasting or
maximum exercise, resulting from an increase in FA in blood
plasma (11,12). Drug binding to HSA can be modulated by
simultaneous binding of FAs (1,5,13), therefore it is impor-
tant to clarify the binding afﬁnity of FA at each FA binding
site on HSA. Very recently, the locations of high afﬁnity FA
binding sites on HSA have been reported (14–16). Simard
et al. showed three high and four low afﬁnity FA binding
sites of palmitate (PLM) on HSA by combining 13C NMR
spectroscopy with drug-competition analysis (15). Kragh-
Hansen et al. investigated high afﬁnity binding sites of
octanoate, decanoate, laurate, and myristate (MYR) by site-
directed mutagenesis of HSA (16). Although these works give
an insight into the binding of FA to HSA, they do not com-
pare the absolute binding afﬁnity of each FA binding site.
Several theoretical methods have recently been developed
to estimate the binding free energy between protein and
ligand, such as free energy perturbation (FEP) (17), the linear
interaction energy (LIE) method (18), and the molecular
mechanics Poisson-Boltzmann surface area (MM-PBSA)
method (19). Of these methods, MM-PBSA is promising
because it requires less computer resources than FEP and,
contrary to LIE, applies no empirical parameters in its free
energy calculations. In MM-PBSA, the binding free energy
of a given protein-ligand complex is calculated by summing
up molecular mechanical energies, solvation energies, and
entropic terms. In addition, by performing molecular dy-
namics (MD) simulation of the given protein-ligand com-
plex, the ensemble averages of these properties are obtained.
MM-PBSA method has been successfully applied to several
‘‘multiple ligands bound to one binding site’’ systems (20–
25). As far as we know, however, there are no published
works that apply the MM-PBSA method to a ‘‘one ligand
bound to multiple binding sites’’ system.
This study was undertaken to quantitatively elucidate high
and low afﬁnity FA binding sites on HSA by MM-PBSA
calculations. This is the ﬁrst report that has applied MM-
PBSA to a ‘‘one ligand (FA) bound to multiple binding sites
(on HSA)’’ system. We focused on the binding of PLM, one
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of the most common FAs transported by HSA in plasma
(26), and MYR, commonly used for examining the effect of
FA on HSA (5,13). In this article, we present the calculated
binding free energy results of two methods, termed the ‘‘three-
trajectory method’’ and the ‘‘single-trajectory method’’. The
former is used to classify high and low afﬁnity FA binding
sites, and the latter to compare the magnitude of binding free
energy among high afﬁnity sites identiﬁed by the former.
Based on the MM-PBSA results, we compare the calculated
binding free energy with the experimental multiple binding
constants (27–29). In addition, we show that conformational
changes in HSA by the binding of one FA molecule differed
according to the binding site.
MATERIALS AND METHODS
Starting structure of HSA-FA complex
The initial coordinates of HSA-FA complex were obtained from the Protein
Data Bank (PDB) (30) (HSA-PLM complex, 1E7H; HSA-MYR complex,
1E7G; the resolutions of the structures were 2.4 and 2.5 A˚, respectively). In
PDB entry 1E7H (8), seven PLM molecules were bound to HSA, and all
were included in the following MD simulations (HSA-7PLM complex). On
the other hand, eight MYR molecules were bound to HSA in PDB entry
1E7G (8). In this study, MYR bound to Site 29 was removed because seven
molecules were bound to the sites, in common with all medium- and long-
chain FAs (8,9). Hence, seven MYR molecules were included in the
following MD simulations (HSA-7MYR complex; Fig. 1).
Molecular dynamics simulations of
HSA-FA complex
A series of MD calculations were carried out using the AMBER8 package
(31). The LEaP module was used for model construction of HSA-FA
complex. The sander module was used for energy minimization, and the
‘‘pmemd’’ module was used for MD calculations. The AMBER (parm94)
force ﬁeld (32) was used for modeling the HSA system. PLM and MYR
force ﬁelds were generated by the antechamber module, based on the general
AMBER force ﬁeld (GAFF) (33). Following ab initio optimization of FA
molecule at the HF/6-31G* level by Gaussian 03 (34), a restrained elec-
trostatic potential ﬁt procedure (35) was used as the charge method in GAFF.
Missing residues in the starting structure of HSA (residues 1, 2, 584, 585)
were added by the Build and Edit Protein tool on DISCOVERY STUDIO
(version 1.5) (36). Following the addition of missing residues, missing
atoms were added by the LEaP module. Energy minimization with con-
straints on the positions of heavy atoms was carried out for 500 steps. Na1
counterions were placed by LEaP to neutralize the negative charges of both
HSA-FA complex models at pH 7. A rectangular-shaped box of water was
constructed using the TIP3P water model (37), with the buffering distance
set to 12 A˚. The resulting model systems contained 97,447 (HSA-7PLM
complex) and 98,473 (HSA-7MYR complex) atoms. The single FA mol-
ecule system was also constructed according to the same criterion, and the
model systems contained 3662 (PLM molecule) and 3440 (MYR molecule)
atoms. For each system, 500 steps of energy minimization constraining the
HSA and/or FA molecules were carried out, followed by 500 steps of energy
minimization with no constraints. After energyminimization, 8-nsMD calcu-
lations were carried out for each HSA-seven FA complex model (HSA-7FA)
under periodic boundary conditions. The nonbonded list was generated
using an atom-based cutoff of 8 A˚. The long-range electrostatic interactions
were handled by the particle-mesh Ewald algorithm (38). The time step of
the MD simulations was set to 2.0 fs, and the SHAKE algorithm (39) was
used to constrain bond lengths at their equilibrium values. Temperature and
pressure were maintained using the weak-coupling algorithm (40) with
coupling constants tT and tP of 1.0 and 0.2 ps, respectively (310 K, 1 atm).
Coordinates were saved for analyses every 1 ps.
Seven HSA-one FA complex models (HSA-1FAs) and the unliganded
HSA model were obtained by removing six or seven other FA molecules
from the snapshot of HSA-7FA complex at 4 ns, with the velocity of each
atom unchanged from that at 4 ns, to prevent from sampling different
conformational space between the HSA models. Starting with seven HSA-
1FA complex models and one unliganded HSA model, additional 4-ns MD
simulations were performed for each model under the same conditions as
above.
The MD simulations and subsequent MM-PBSA calculations were run
on an in-house PC cluster composed of eight nodes (AMDOpteron 2.2 GHz,
2 GB DDR memory; Sunnyvale, CA) with a gigabit Ethernet interconnec-
tion.
MM-PBSA calculations for binding free energy
Binding free energy (DGbind) of FA at each FA binding site on HSA was
calculated as follows:
DGbind ¼ Gcomplex  GHSA  GFA; (1)
where Gcomplex, GHSA, and GFA are the free energies of complex, HSA, and
FA, respectively. Free energy (G) of each state was calculated as follows:
G ¼ EMM1GPB1GSA  TS (2)
EMM ¼ Evdw1Eele1Eint; (3)
where EMM is the molecular mechanical energy, GPB and GSA are the
contributions from polar and nonpolar terms of the free energy of the solvent
continuum, and TS is the entropic contribution of the solute. EMM was
obtained by summing contributions from internal energies including bond,
angle, and torsional angle energies (Eint), electrostatic energy (Eele), and
van der Waals energy (Evdw), using the same force ﬁeld as that of MD
simulations with no cutoff. GPB was calculated using the DELPHI program
(41) with PARSE (42) atom radii and standard AMBER94 charges (32) for
amino acids. The dielectric constants inside and outside the molecule were
FIGURE 1 Ribbon model of HSA-MYR complex, derived from x-ray
crystallography (PDB entry 1E7G). HSA is composed of three homologous
domains I–III, each of which is divided into two subdomains, A and B. The
seven MYR molecules are shown in black in a space-ﬁlling representation.
Numbering of the sites is taken from Bhattacharya et al. (8). This diagram
was generated using visual molecular dynamics (VMD version 1.8.5) (51).
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1.0 and 80.0, respectively. GSA was calculated using a solvent accessible
surface area (SASA) as follows:
GSA ¼ g3 SASA1 b: (4)
The SASA was computed with the ‘‘molsurf’’ module in AMBER8 (31),
using a probe radius of 1.4 A˚. The surface tension proportionality constant
(g) and the free energy of nonpolar solvation for a point solute (b) were set to
0.00542 kcal/mol/A˚2 and 0.92 kcal/mol, respectively (42). Estimates of
conformational entropies were computed with the ‘‘nmode’’ module in
AMBER8 (30). Entropic contributions from translational and rotational
motion were taken from classical statistical thermodynamics (43), and en-
tropic contribution from vibrational motion was obtained by normal mode
analysis (44). Following energy minimization of the snapshot with a
distance-dependent dielectric function (e ¼ 4Rij) until the root mean-square
of the elements of the gradient vector was,104 kcal/mol/A˚, frequencies of
the vibrational modes were computed at 300 K for the minimized structures
using a harmonic approximation of the energies.
For the binding free energy calculations by MM-PBSA, 500 snapshots of
each model were taken at time intervals of 6 ps from the 3-ns production runs
(5–8 ns). However, entropic contributions were evaluated for only 20 snap-
shots taken at time intervals of 150 ps from the 3-ns production runs,
because of the rather large computational expense. In addition, only sub-
domains of HSA that participated in the binding of FA were used for
calculating the entropic contribution (Site 1, IB; Site 2, IA, IB, IIA; Site 3,
IIB, IIIA; Site 4, IIIA; Site 5, IIIB; Site 6, IIA, IIB; Site 7, IB, IIA).
Three-trajectory method and
single-trajectory method
In these MM-PBSA calculations, two trajectory set methods were per-
formed. The ‘‘three-trajectory method’’ used snapshots extracted from three
trajectories of complex, FA, and unliganded HSA and the ‘‘single-trajectory
method’’ used snapshots extracted from a single trajectory of the HSA-FA
complex. The binding free energy of the three-trajectory method was
calculated as follows:
DGbind ¼ ÆGcomplexæ ÆGHSAæ ÆGFAæ; (5)
where Æ    æ denotes an average of snapshots taken from MD trajectories.
The binding free energy was calculated for the single-trajectory method, as
follows:
DGbind ¼ ÆGcomplex  GHSA  GFAæ: (6)
It should be noted that the change in internal energies (DEint) equals zero in
calculating the binding free energy according to Eq. 6, since the internal energies
of the complex and the separated parts are calculated from the same trajectory.
RESULTS AND DISCUSSION
Root mean-square deviation of HSA-FA complex
and unliganded HSA
The root mean-square deviation (RMSD) of Ca atoms from
the x-ray structure in HSA-FA complex systems are shown
in Fig. 2. In each system, RMSD values reached plateau at
;2 ns (see Fig. 2 A). Calculated from the 4- to 8-ns trajectory
data, the RMSD values of Ca atoms in the whole HSA
molecules were 2.58 6 0.23 A˚ and 3.03 6 0.23 A˚ for HSA-
7MYR complex and HSA-7PLM complex, respectively. We
also calculated the RMSD of Ca atoms in each subdomain to
analyze which region of HSA undergoes large conforma-
tional changes (Fig. 3). In both HSA-7FA models, subdo-
mains IA and IIIB showed larger RMSD values, suggesting
that larger conformational changes occur at these subdo-
mains. Some of the recent MD studies, which were carried
out under similar conditions with these MD simulations,
reported that the RMSD values reached between 2 and 4 A˚
(45,46). Taking into account of the relatively low resolution
of the crystal structures of HSA (2.4–2.5 A˚), we conclude
that no signiﬁcant structural drift from the x-ray structure
occurred during the MD simulations.
Additional 4-ns MD of unliganded HSA models also
showed that no signiﬁcant structural drift occurred during the
MD simulations and that RMSD values reached plateau at
;5 ns in both systems (Fig. 2 B). For the HSA-1FA complex
models, RMSD also reached plateau at ;5 ns (see Supple-
mentary Material). In comparisons of the unliganded HSA
models with the crystal structure of unliganded HSA (PDB
entry 1AO6), RMSD values of Ca atoms in the whole HSA
molecule were 3.40 6 0.20 A˚ (from HSA-7PLM complex)
and 5.07 6 0.40 A˚ (from HSA-7MYR complex), calculated
from the 5- to 8-ns trajectory. Although the RMSD value
FIGURE 2 Time evolution of the RMSD of Ca atoms from the starting
structure during 8-ns MD simulations of HSA-7FA complex models (A), and
4- to 8-ns simulations of unliganded HSA models (B).
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from the crystal structure was large in unliganded HSA
model constructed from the HSA-7MYR complex, the
RMSD value in each FA binding site (Site 1–7) was between
2 and 4 A˚, suggesting that no signiﬁcant structural drift from
the crystal structure occurred in each FA binding site on
HSA. Therefore, the deviations from the crystal structure
observed as above may not affect signiﬁcantly the binding
free energy calculation by the three-trajectory method. In this
study, we used from 5- to 8-ns trajectories in the following
MM-PBSA calculations.
Two types of MM-PBSA for identifying high afﬁnity
FA sites
The single-trajectory method (Eq. 6) has been used in many
MM-PBSA studies owing to the considerable reduction in
computer time due to MD simulation for only one complex
model (20,21,25,47). On the basis that large conformational
changes do not occur upon binding, the single-trajectory
approach has the beneﬁt of error cancellation in internal
energies (DEint) and high correlation between variations of
Gcomplex and (GHSA 1 GFA), resulting in precise estimation
of the binding free energy. In this study, however, confor-
mational changes of HSA by the binding of FAs have been
reported (6,48), and the contribution of each FA binding site
to the conformational changes upon FA binding may be
different. Therefore, the single-trajectory method, which
cannot include the effect of conformational changes on HSA
by the binding of FA, may not be appropriate for ranking the
binding free energies among FA binding sites with confor-
mational changes.
On the other hand, the three-trajectory method (Eq. 5)
does have value in that it may calculate total free energy
change, including intramolecular strain, characterized as
DEint, and an induced ﬁt effect, by the binding of FA on
HSA. In fact, some articles reported the signiﬁcant effect of
including DEint in the binding free energy (47,49). However,
the three-trajectory method is less precise compared to the
single-trajectory method because it includes an additional
source for errors, the contribution of internal energy term
(DEint), and does not include cancellation of errors derived
from correlation between variations ofGcomplex and (GHSA1
GFA) (23,47). Because of the additional errors, the three-
trajectory method may not be appropriate for ranking the
binding free energy of each FA binding site, especially with
similar binding conformations.
In this study, based on the characteristics of the two types
of MM-PBSA as mentioned above, we used the two methods
in the following way: in comparisons between FA binding
sites where large conformational changes can occur upon
binding, the three-trajectory method may be more accurate
for calculation of binding free energy than the single-
trajectory method. Furthermore, contributions from each
energy component in HSA-FA interactions are assumed to
be quite different between high afﬁnity and low afﬁnity sites.
Taking these points into account, we ﬁrst used the three-
trajectory method to classify high and low afﬁnity FA bind-
ing sites on HSA. In addition, even if conformational
changes occur upon FA binding, it can be expected that, at
favorable FA binding sites, a given FA molecule binds to
each site in a similar way. Thus the binding energies can be
compared between the sites, although some bias, which is in
common with all the sites, may be involved in the estimation.
Based on this assumption, we next used the single-trajectory
method to compare the magnitude of binding free energy
between high FA binding sites.
FIGURE 3 Time evolution of the RMSD of Ca
atoms belonging to each subdomain of HSA-7FA
complex model from the starting structure during
8-ns MD simulations. All Ca atoms were ﬁtted to
the starting structure.
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MM-PBSA for binding of palmitate on HSA
Table 1 shows the calculated binding free energy compo-
nents of HSA-1PLM complex based on the three-trajectory
method. The binding free energy (DGbind) indicated large
positive values at Sites 6 and 7. In the ﬁrst published work
regarding x-ray crystallographic analysis of HSA-MYR
complex, only Sites 1–5 were detected using a lower FA to
protein molar ratio (6), suggesting that Sites 6 and 7 are low
afﬁnity FA binding sites. The results of this study were
consistent with those of previous work. In addition, the
binding free energy indicated large positive values at Site 3
(18.0 kcal/mol), which is also in accordance with previous
work reporting that the binding of PLM at Site 3 is weak
(15). Consequently, we identiﬁed Sites 3, 6, and 7 as low
afﬁnity PLM binding sites. Simard et al. (15) reported that
three high (Sites 2, 4, and 5) and four low PLM binding sites
(Sites 1, 3, 6, and 7) exist on HSA. In this study, the
magnitude of the binding free energy at Site 1 (although a
negative value was indicated) was much smaller than that of
Sites 2, 4, and 5 (Table 1), suggesting that the binding
afﬁnity at Site 1 is weaker than that of the other three sites.
Table 2 shows the calculated binding free energy compo-
nents of HSA-1PLM complex using the single-trajectory
method. Focused on high afﬁnity binding sites identiﬁed by
the three-trajectory method (Sites 2, 4, and 5), the order of
the binding free energy was 5 . 4 . 2. This result was in
line with previous work by Simard et al. (15). Because the
other PLM binding sites (Sites 1, 3, 6, 7) were already
identiﬁed as low afﬁnity sites by the three-trajectory method,
we did not include these binding sites in comparison of the
binding free energy by the single-trajectory method, although
the binding free energy at Sites 1 and 3 indicated relatively
large negative values by the single-trajectory method. If only
the result of single-trajectory method was used, the trend of
binding afﬁnity was 5 . 1 . 3 . 4 . 2 . 7 . 6, and Sites
1 and 3 might be misclassiﬁed as high afﬁnity FA binding
sites.
In summary, we identiﬁed Sites 2, 4, and 5 as high afﬁnity
PLM binding sites, where Site 5 was the highest afﬁnity
binding site. In addition, this study indicated that a com-
bination of the three-trajectory and single-trajectory methods
are effective in MM-PBSA calculations for determining high
and low afﬁnity binding sites, and the order of afﬁnity for the
high afﬁnity sites.
MM-PBSA for binding of myristate on HSA
We performed MM-PBSA calculations for the binding of
MYR on HSA. Table 3 shows the calculated binding free
energy components of HSA-1MYR complex based on the
three-trajectory method. The binding free energy indicated
large positive values at Sites 1, 3, 6, and 7, suggesting that
these sites are low afﬁnity binding sites for MYR. At Sites 2,
4, and 5, the binding free energy showed near-zero or
negative values, indicating that they are high afﬁnity MYR
binding sites on HSA. The present MM-PBSA result was a
little inconsistent with previous experimental work by
Kragh-Hansen et al. (16), which reports that Sites 1, 5, and
4 are high afﬁnity MYR binding sites on HSA. However, the
group did not check the binding afﬁnity of MYR at Site 2,
because they have not yet produced mutants for Site 2 (16).
Considering that only a small difference in carbon chain
length exists between PLM (C16) and MYR (C14), similar
binding modes are expected between these FAs. It might be
TABLE 1 Binding free energy components of HSA-1PLM
complex in the three-trajectory method (in units of kcal/mol)
DEele* DEvdw DEint DGSA DGPB DGmmpbsa
y TDSz DGbind
§
Site 1 166.7 19.1 2.9 1.8 175.8 32.9 20.5 12.4
(9.8) (2.4) (4.4) (0.1) (9.1) (5.7) (1.5) (5.9)
Site 2 131.1 12.0 2.3 2.6 262.2 124.0 15.8 108.1
(10.7) (2.6) (4.4) (0.2) (10.7) (5.5) (3.3) (6.4)
Site 3 65.0 24.2 4.6 4.9 43.2 2.8 20.8 18.0
(9.9) (2.4) (4.4) (0.1) (10.7) (5.6) (2.5) (6.2)
Site 4 111.1 21.3 0.9 3.0 151.4 63.7 17.9 45.8
(9.6) (2.5) (4.4) (0.1) (9.7) (5.7) (1.9) (6.0)
Site 5 16.5 0.7 25.2 0.7 40.3 49.0 16.2 32.8
(8.7) (2.5) (4.4) (0.1) (8.7) (5.3) (1.6) (5.5)
Site 6 87.6 14.5 5.9 3.6 44.7 18.8 23.7 42.4
(9.4) (2.5) (4.4) (0.1) (9.4) (5.6) (2.5) (6.2)
Site 7 187.3 44.1 2.5 6.1 120.3 14.3 19.6 33.8
(8.6) (2.4) (4.2) (0.1) (8.8) (5.2) (2.8) (5.9)
*Number in parentheses is mean 6 SE.
yDGmmpbsa ¼ DGele1DGvdw1DGint1DGSA1DGPB:
zThe absolute temperature (T) was set to 300 K in the MM-PBSA calcu-
lations.
§DGbind was calculated according to Eq. 5.
TABLE 2 Binding free energy components of HSA-1PLM
complex in the single-trajectory method (in units of kcal/mol)
DEele DEvdw DGSA DGPB DGmmpbsa TDS DGbind
Site 1* 10.5 43.8 5.7 27.9 32.1 21.0 11.0
(0.2) (0.1) (0.007) (0.2) (0.2) (0.9) (0.9)
Site 2 4.4 41.5 6.0 23.7 28.1 20.0 8.1
(0.2) (0.1) (0.008) (0.3) (0.2) (2.1) (2.2)
Site 3 12.9 44.5 5.5 34.1 28.8 19.6 9.2
(0.1) (0.1) (0.008) (0.2) (0.2) (1.4) (1.4)
Site 4 13.2 45.7 5.8 35.7 28.9 20.0 8.9
(0.2) (0.1) (0.004) (0.2) (0.2) (1.5) (1.5)
Site 5 23.2 46.4 5.6 45.0 30.2 18.1 12.0
(0.4) (0.1) (0.006) (0.3) (0.2) (1.1) (1.1)
Site 6 6.4 44.8 5.6 29.8 27.0 23.4 3.6
(0.2) (0.1) (0.005) (0.2) (0.2) (1.7) (1.7)
Site 7 16.1 40.5 5.6 38.2 24.1 17.6 6.4
(0.2) (0.1) (0.010) (0.2) (0.2) (1.5) (1.5)
*See footnotes of Table 1; however, DGbind was calculated according to Eq. 6.
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possible that Site 2 and not Site 1 is one of the high afﬁnity
FA binding sites for MYR.
We also calculated binding free energy components of
HSA-1MYR complex using the single-trajectory method
(Table 4). Focusing on high afﬁnity binding sites identiﬁed
by the three-trajectory method (Sites 2, 4, and 5), the order of
the binding free energy was 5. 4. 2, thus corresponding to
the present MM-PBSA calculations for PLM. Combining the
results of the single-trajectory and three-trajectory methods,
we identiﬁed Sites 2, 4, and 5 as high afﬁnity MYR binding
sites, where Site 5 was the highest afﬁnity binding site, as is
the case with PLM.
Difference in ranking of the binding free energy
between two types of MM-PBSA
The order of the magnitude of binding free energy at each FA
binding site using the single-trajectory method did not
coincide with that of the three-trajectory method, particularly
for MYR. The difference between the two methods deﬁnes
whether or not intramolecular strain, characterized as DEint,
and induced ﬁt effects are included with the calculated
binding free energy. The intramolecular strain, caused by the
binding of FA on HSA, was different at each FA binding site,
as shown in Tables 1 and 3. Remarkable changes in strain
were observed at Site 5 for PLM binding, and at Sites 2, 4,
and 5 for MYR binding.
In addition, we analyzed how much induced ﬁt occurred
by the binding of FA to each FA binding site on HSA. Table
5 shows RMSDs of Ca atoms of unliganded HSA and
HSA-1FA complex (5–8 ns) from unliganded HSA at 6 ns.
RMSDs of each HSA-1FA complex binding site increased
by FA binding, indicating that an induced ﬁt effect occurred
upon binding of FA to HSA. The extent of the increase in
RMSD differed among FA binding sites, and more than 1 A˚
increase in RMSD was observed at Sites 1, 2, and 5 for PLM
binding, and Sites 1 and 5 for MYR binding. It is interesting
to note that the sites indicating large ﬂuctuation (RMSD of
Ca atoms) were not necessarily large in DEint, such as Site 1.
By contraries, a large deviation was not observed at Site 3. If
intramolecular strain was considered in the single-trajectory
method (Table 4), the actual magnitude of the binding free
energy of MYRmight be larger at Sites 4 and 5 than at Site 3.
This is because the intramolecular strain is more favorable at
Sites 4 and 5, as shown in Table 3. In addition, taking into
account the large conformational change observed at Site 5
by the binding of MYR, it is possible that the conformational
change leads to more favorable FA—and thus highest—
binding at Site 5. Although these differences do not directly
explain the difference in the order of magnitude of binding
free energy between the two methods, it is implied that both
intramolecular strain and induced ﬁt were intricately inter-
related and caused a marked effect on the binding free
energy.
TABLE 3 Binding free energy components of HSA-1MYR
complex in the three-trajectory method (in units of kcal/mol)
DEele DEvdw DEint DGSA DGPB DGmmpbsa TDS DGbind
Site 1* 225.9 26.4 1.5 4.2 172.0 21.8 16.2 38.0
(12.0) (2.6) (4.5) (0.2) (11.1) (5.1) (1.5) (5.3)
Site 2 77.5 28.0 18.1 4.2 115.9 52.5 15.1 37.4
(11.8) (2.6) (4.6) (0.1) (10.3) (5.5) (3.1) (6.3)
Site 3 339.6 40.6 6.6 3.4 268.3 20.7 19.7 40.4
(11.1) (2.5) (4.6) (0.1) (10.2) (5.0) (2.2) (5.5)
Site 4 406.3 22.5 22.5 0.8 375.0 8.0 14.0 6.0
(11.1) (2.4) (4.5) (0.1) (10.4) (5.0) (1.9) (5.3)
Site 5 440.6 13.9 11.7 1.6 458.7 14.2 21.4 7.2
(11.5) (2.8) (4.5) (0.1) (10.8) (5.1) (1.6) (5.3)
Site 6 316.7 22.7 2.1 2.9 283.6 5.4 19.6 25.0
(12.0) (2.6) (4.5) (0.1) (11.0) (5.0) (2.0) (5.4)
Site 7 204.0 1.0 2.3 3.2 194.0 8.1 21.5 29.7
(12.3) (2.6) (4.5) (0.1) (11.1) (5.2) (1.4) (5.4)
*See footnotes of Table 1.
TABLE 4 Binding free energy components of HSA-1MYR
complex in the single-trajectory method (in units of kcal/mol)
DEele DEvdw DGSA DGPB DGmmpbsa TDS DGbind
Site 1* 3.0 37.6 5.3 17.2 28.8 18.3 10.5
(0.1) (0.2) (0.01) (0.2) (0.2) (1.0) (1.0)
Site 2 7.9 39.2 5.5 27.0 25.5 22.0 3.6
(0.2) (0.1) (0.004) (0.2) (0.2) (2.4) (2.4)
Site 3 34.9 37.5 5.2 42.5 35.1 20.2 15.0
(0.3) (0.2) (0.01) (0.2) (0.2) (1.4) (1.4)
Site 4 6.4 36.9 5.3 18.3 30.3 18.7 11.7
(0.3) (0.1) (0.006) (0.2) (0.2) (1.8) (1.9)
Site 5 10.6 41.5 5.2 24.0 33.3 18.4 14.9
(0.2) (0.1) (0.006) (0.2) (0.2) (1.1) (1.1)
Site 6 4.2 39.4 5.2 21.8 27.0 21.4 5.6
(0.1) (0.1) (0.005) (0.2) (0.2) (1.4) (1.4)
Site 7 11.0 31.8 5.1 25.8 22.1 18.1 4.0
(0.4) (0.1) (0.007) (0.4) (0.2) (2.2) (2.2)
*See footnotes of Table 1; however, DGbind was calculated according to Eq. 6.
TABLE 5 Root mean-square deviation of each FA binding site
of unliganded HSA and HSA-1FA complex (5–8 ns) from
unliganded HSA at 6 ns (in units of A˚)
Palmitate Myristate
Unliganded Complex Unliganded Complex
Site 1 (108–196) 1.26 6 0.32 2.62 6 0.20 1.06 6 0.16 2.10 6 0.16
Site 2 (1–297) 1.75 6 0.37 2.87 6 0.18 1.38 6 0.24 1.70 6 0.22
Site 3 (298–497) 1.19 6 0.16 2.07 6 0.31 1.33 6 0.21 1.69 6 0.15
Site 4 (384–497) 0.91 6 0.18 1.50 6 0.10 1.02 6 0.20 1.52 6 0.10
Site 5 (498–585) 1.07 6 0.22 2.08 6 0.17 1.27 6 0.27 3.41 6 0.37
Site 6 (197–383) 1.19 6 0.20 1.52 6 0.15 1.30 6 0.19 1.70 6 0.16
Site 7 (108–297) 1.29 6 0.30 2.00 6 0.17 1.38 6 0.29 1.97 6 0.25
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Comparison of calculated binding free energy with
experimental afﬁnity data
How well do the binding free energies calculated by MM-
PBSA calculations correspond to the experimental binding
afﬁnity constant? We compared the experimental afﬁnity
constants (27–29) with the calculated binding free energies
of the single-trajectory method. Fig. 4 shows the relationship
between experimental and calculated binding free energy for
the three high afﬁnity FA binding sites (Sites 2, 4, and 5).
Many of the calculated binding free energies deviated greatly
from the experimental binding free energies, as shown in Fig.
4. Furthermore, the calculated binding free energies of PLM
were smaller than those of MYR. This result was inconsis-
tent with previous reports showing that the magnitude of the
afﬁnity constant increased as the carbon chain length of the
FA increased (16,27,29,50). It is reported that weak and
strong binders that differ ,2–3 orders of magnitude in IC50
(corresponding to DDGbind # 4.8 kcal/mol) are poorly dis-
tinguished by MM-PBSA (24), and this comparison between
PLM and MYR may be attributed to this. More rigorous
approaches are required to accurately estimate the binding
free energy of each ligand.
On the other hand, the binding free energies calculated by
the three-trajectory method (Tables 1 and 3) were much more
deviated from the experimental binding free energies. As
mentioned above, one of the reasons may be that the three-
trajectory method is less precise than the single-trajectory
method. Furthermore, the free energies (Gmmpbsa) of the two
unliganded HSA models constructed from the HSA-7FA mod-
els were quite different between each other (19,581.2 6
93.7 kcal/mol and 17,633.2 6 80.5 kcal/mol from HSA-
7PLM complex and HSA-7MYR complex, respectively),
suggesting that only a limited conformational space was used
for the binding free energy calculation by the three-trajectory
method. By sampling a full conformational space from each
HSA and HSA-FA model, the calculated binding free
energies may be more comparable with the experimental
binding free energies; however, it is remarkably difﬁcult to
get enough conformational space of HSA, as in our previous
study, reporting that even 10-ns MD simulations did not get a
full impression of the conformational freedom of HSA (48).
Change in radius of gyration of HSA by binding of
fatty acids
Under normal physiological conditions, HSA binds with
;0.1–2 mol of FA per mol of protein (10), and the molar
ratio of FA/HSA can rise up to 6 during fasting or maximum
exercise (11,12). Based on these MD simulations, we ana-
lyzed conformational changes of unliganded HSA by the
binding of FAs. Table 6 summarizes the radius of gyration
(Rg) of unliganded HSA and HSA-1FA complexes, obtained
from the 5- to 8-ns trajectory data from MD simulations. We
modeled HSA under normal physiological conditions as the
HSA-1FA complex in which FA is bound to Site 2, 4, or 5
(identiﬁed as high afﬁnity FA binding sites), and during
fasting or maximum exercise as the HSA-7FA complex. The
binding of seven FA molecules to HSA caused an increase in
Rg of unliganded HSA, in line with previous studies (6,48).
It is interesting that the binding of one FA molecule at Site 5
also caused a remarkable increase in Rg. In this study, Site 5
was identiﬁed as the highest binding afﬁnity site, and it is
suggested that induced ﬁt caused the increase, as shown in
Table 5. Thus, it is supposed that the total volume of HSA
under normal physiological conditions is larger than that of
unliganded HSA.
CONCLUSION
In this study, high and low afﬁnity FA binding sites on HSA
were discussed quantitatively, based on the results of MM-
PBSA calculations. According to the two trajectory set
methods, three high afﬁnity FA binding sites and the order of
TABLE 6 Radius of gyration of unliganded HSA and HSA-FA
complex based on 5- to 8-ns MD simulations (in units of A˚)
MYR PLM
Unliganded HSA 27.63 6 0.10 27.61 6 0.15
HSA-7FA 28.54 6 0.17 28.40 6 0.27
HSA-1FA (Site 2) 27.59 6 0.11 27.81 6 0.40
HSA-1FA (Site 4) 27.69 6 0.12 27.67 6 0.18
HSA-1FA (Site 5) 28.33 6 0.15 27.90 6 0.15
FIGURE 4 Relationship between experimental and calculated binding
free energy for the three high afﬁnity FA binding sites (Sites 5, 4, 2). Afﬁnity
constants (K1, K2, K3) were taken from references, where the circle, triangle,
and square symbols are corresponding to Ashbrook et al. (27), Pedersen
et al. (28), and Richieri et al. (29). The experimental binding free energy
(DGbind,expt) was calculated byRT lnK; where R and T are the gas constant
and the absolute temperature, respectively.
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the magnitude of these three FA binding sites were identiﬁed
for PLM and MYR. The radius of gyration of unliganded
HSA increased remarkably by the binding of one FA
molecule to the highest FA binding site, Site 5. Thus, this
study revealed high and low FA binding sites for PLM and
MYR, and possible conformational changes of HSA by the
binding of FAs. In addition, this study illustrated the efﬁcacy
of combining the three-trajectory and single-trajectory meth-
ods. However, more rigorous approaches are required to
accurately estimate the binding free energy. Nevertheless,
the present MM-PBSA calculations agreed well with exper-
imentally determined high and low FA binding sites. This
analysis can be applied to the other FAs bound to HSA, as
well as other ‘‘one ligand bound to multiple binding sites’’
systems. In conclusion, this study theoretically makes an
important contribution to the identiﬁcation of high afﬁnity
FA binding sites on HSA.
SUPPLEMENTARY MATERIAL
To view all of the supplemental ﬁles associated with this
article, visit www.biophysj.org.
This study was supported in part by Grants-in-Aid for Scientiﬁc Research
from the Ministry of Education, Culture, Sports, Science, and Technology
of Japan.
REFERENCES
1. Kragh-Hansen, U., V. T. G. Chuang, and M. Otagiri. 2002. Practical
aspects of the ligand-binding and enzymatic properties of human serum
albumin. Biol. Pharm. Bull. 25:695–704.
2. He, X. M., and D. C. Carter. 1992. Atomic structure and chemistry of
human serum albumin. Nature. 358:209–215.
3. Dockal, M., D. C. Carter, and F. Ruker. 1999. The three recombinant
domains of human serum albumin. Structural characterization and
ligand binding properties. J. Biol. Chem. 274:29303–29310.
4. Sugio, S., A. Kashima, S. Mochizuki, M. Noda, and K. Kobayashi.
1999. Crystal structure of human serum albumin at 2.5 A˚ resolution.
Protein Eng. 12:439–446.
5. Ghuman, J., P. A. Zunszain, I. Petitpas, A. A. Bhattacharya, M. Otagiri,
and S. Curry. 2005. Structural basis of the drug-binding speciﬁcity of
human serum albumin. J. Mol. Biol. 353:38–52.
6. Curry, S., H. Mandelkow, P. Brick, and N. Franks. 1998. Crystal
structure of human serum albumin complexed with fatty acid reveals an
asymmetric distribution of binding sites. Nat. Struct. Biol. 5:827–835.
7. Curry, S., P. Brick, and N. Franks. 1999. Fatty acid binding to human
serum albumin: new insights from crystallographic studies. Biochim.
Biophys. Acta. 1441:131–140.
8. Bhattacharya, A. A., T. Gru¨ne, and S. Curry. 2000. Crystallographic
analysis reveals common modes of binding of medium and long-chain
fatty acids to human serum albumin. J. Mol. Biol. 303:721–732.
9. Petitpas, I., T. Gru¨ne, A. A. Bhattacharya, and S. Curry. 2001. Crystal
structures of human serum albumin complexed with monounsaturated
and polyunsaturated fatty acids. J. Mol. Biol. 314:955–960.
10. Fredrickson, D. S., and R. S. Gordon. 1958. The metabolism of
albumin-bound C14-labeled unesteriﬁed fatty acids in normal human
subjects. J. Clin. Invest. 37:1504–1515.
11. Brodersen, R., S. Andersen, H. Volum, S. U. Nielsen, and A. O.
Pedersen. 1990. Multiple fatty acid binding to albumin in human blood
plasma. Eur. J. Biochem. 189:343–349.
12. Bahr, R., A. T. Høstmark, E. A. Newsholme, O. Grønnedød, and O. M.
Sejersted. 1991. Effect of exercise on recovery changes in plasma
levels of FFA, glycerol, glucose and catecholamines. Acta Physiol.
Scand. 143:105–115.
13. Chuang, V. T., and M. Otagiri. 2002. How do fatty acids cause allo-
steric binding of drugs to human serum albumin? Pharm. Res. 19:
1458–1464.
14. Simard, J. R., P. A. Zunszain, C. E. Ha, J. S. Yang, N. V. Bhagavan, I.
Petitpas, S. Curry, and J. A. Hamilton. 2005. Locating high-afﬁnity
fatty acid-binding sites on albumin by x-ray crystallography and NMR
spectroscopy. Proc. Natl. Acad. Sci. USA. 102:17958–17963.
15. Simard, J. R., P. A. Zunszain, J. A. Hamilton, and S. Curry. 2006.
Location of high and low afﬁnity fatty acid binding sites on human
serum albumin revealed by NMR drug-competition analysis. J. Mol.
Biol. 361:336–351.
16. Kragh-Hansen, U., H. Watanabe, K. Nakajou, Y. Iwao, and M. Otagiri.
2006. Chain length-dependent binding of fatty acid anions to human
serum albumin studied by site-directed mutagenesis. J. Mol. Biol.
363:702–712.
17. Rao, S. N., U. C. Singh, P. A. Bash, and P. A. Kollman. 1987. Free
energy perturbation calculations on binding and catalysis after mutating
Asn 155 in subtilisin. Nature. 328:551–554.
18. Hansson, T., J. Marelius, and J. A˚qvist. 1998. Ligand binding afﬁnity
prediction by linear interaction energy methods. J. Comput. Aided Mol.
Des. 12:27–35.
19. Srinivasan, J., T. E. Cheatham, P. Cieplak, P. A. Kollman, and D. A.
Case. 1998. Continuum solvent studies of the stability of DNA, RNA,
and phosphoramidate-DNA helices. J. Am. Chem. Soc. 120:9401–
9409.
20. Wang, J., P. Morin, W. Wang, and P. A. Kollman. 2001. Use of
MM-PBSA in reproducing the binding free energies to HIV-1 RT of
TIBO derivatives and predicting the binding mode to HIV-1 RT
of efavirenz by docking and MM-PBSA. J. Am. Chem. Soc. 123:5221–
5230.
21. Huo, S., J. Wang, P. Cieplak, P. A. Kollman, and I. D. Kuntz. 2002.
Molecular dynamics and free energy analyses of cathepsin D-inhibitor
interactions: insight into structure-based ligand design. J. Med. Chem.
45:1412–1419.
22. Fogolari, F., A. Brigo, and H. Molinari. 2003. Protocol for MM/PBSA
molecular dynamics simulations of proteins. Biophys. J. 85:159–166.
23. Gohlke, H., and D. A. Case. 2004. Converging free energy estimates:
MM-PB(GB)SA studies on the protein-protein complex Ras-Raf.
J. Comput. Chem. 25:238–250.
24. Kuhn, B., P. Gerber, T. Schulz-Gasch, and M. Stahl. 2005. Validation
and use of the MM-PBSA approach for drug discovery. J. Med. Chem.
48:4040–4048.
25. Xu, Y., and R. Wang. 2006. A computational analysis of the bind-
ing afﬁnities of FKBP12 inhibitors using the MM-PB/SA method.
Proteins. 64:1058–1068.
26. Saifer, A., and L. Goldman. 1961. The free fatty acids bound to human
serum albumin. J. Lipid Res. 2:268–270.
27. Ashbrook, J. D., A. A. Spector, E. C. Santos, and J. E. Fletcher. 1975.
Long chain fatty acid binding to human plasma albumin. J. Biol. Chem.
250:2333–2338.
28. Pedersen, A. O., and R. Brodersen. 1988. Myristic acid binding to
human serum albumin investigated by dialytic exchange rate. J. Biol.
Chem. 263:10236–10239.
29. Richieri, G. V., A. Anel, and A. M. Kleinfeld. 1993. Interactions of
long-chain fatty acids and albumin: determination of free fatty acid
levels using the ﬂuorescent probe ADIFAB. Biochemistry. 32:7574–
7580.
30. Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H.
Weissig, I. N. Shindyalov, and P. E. Bourne. 2000. The Protein Data
Bank. Nucleic Acids Res. 28:235–242.
31. Case, D. A., T. A. Darden, T. E. Cheatham, III, C. L. Simmerling,
J. Wang, R. E. Duke, R. Luo, K. M. Merz, B. Wang, D. A. Pearlman,
102 Fujiwara and Amisaki
Biophysical Journal 94(1) 95–103
M. Crowley, S. Brozell, V. Tsui, H. Gohlke, J. Mongan, V. Hornak, G.
Cui, P. Beroza, C. Schafmeister, J. W. Caldwell, W. S. Ross, and P. A.
Kollman. AMBER8. University of California, San Francisco, CA.
32. Cornell, W. D., P. Cieplak, C. I. Bayly, I. R. Gould, K. M. Merz Jr.,
D. M. Ferguson, D. C. Spellmeyer, T. Fox, J. W. Caldwell, and P. A.
Kollman. 1995. A second generation force ﬁeld for the simulation of
proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117:
5179–5197.
33. Wang, J., R. M. Wolf, J. W. Caldwell, P. A. Kollman, and D. A. Case.
2004. Development and testing of a general Amber force ﬁeld.
J. Comput. Chem. 25:1157–1173.
34. Frisch, M. J., G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A.
Robb, J. R. Checseman, J. A. Montgomery Jr, T. Vrcven, K. N. Kudin,
J. C. Burant, J. C. Millam, S. S. Iyengar, J. Tomasi, V. Barone,
B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson,
H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa,
M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li,
J. E. Knox, H. P. Hratchian, J. B. Cross, C. Adamo, J. Jaramillo,
R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi,
C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth,
P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D.
Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck,
K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul,
S. Clifford, J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko,
P. Piskorz, I. Komaromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-
Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill,
B. Johnson, W. Chen, M. W. Wong, C. Gonzalez, and J. A. Pople.
GAUSSIAN 03, Revision A.1. Gaussian, Pittsburgh, PA.
35. Bayly, C. I., P. Cieplak, W. D. Cornell, and P. A. Kollman. 1993. A
well-behaved electrostatic potential based method using charge re-
straints for deriving atomic charges. The RESP model. J. Phys. Chem.
97:10269–10280.
36. Accelrys, Inc. DISCOVERY STUDIO. Accelrys, San Diego, CA.
37. Jorgensen, W. L., J. Chandrasekhar, J. D. Madura, R. W. Impey, and
M. L. Klein. 1983. Comparison of simple potential functions for
simulating liquid water. J. Chem. Phys. 79:926–935.
38. Darden, T., D. York, and L. Pedersen. 1993. Particle mesh Ewald—an
Nlog(N) method for Ewald sums in large systems. J. Chem. Phys. 98:
10089–10092.
39. Van Gunsteren, W. F., and H. J. C. Berendsen. 1977. Algorithm for
macromolecular dynamics and constraint dynamics. Mol. Phys. 34:
1311–1327.
40. Berendsen, H. J. C., J. P. M. Postma, W. F. van Gunsteren, A. DiNola,
and J. R. Haak. 1984. Molecular dynamics with coupling to an external
bath. J. Chem. Phys. 81:3684–3690.
41. Honig, B., and A. Nicholls. 1995. Classical electrostatics in biology
and chemistry. Science. 268:1144–1149.
42. Sitkoff, D., K. A. Sharp, and B. Honig. 1994. Accurate calculation of
hydration free-energies using microscopic solvent models. J. Phys.
Chem. 98:1978–1988.
43. McQuarrie, D. A. 1976. Statistical Mechanics. Harper & Row, NY.
44. Kottalam, J., and D. A. Case. 1990. Langevin modes of macromol-
ecules: application to crambin and DNA hexamers. Biopolymers.
29:1409–1421.
45. Lanig, H., O. G. Othersen, F. R. Beierlein, U. Seidel, and T. Clark.
2006. Molecular dynamics simulations of the tetracycline-repressor
protein: the mechanism of induction. J. Mol. Biol. 359:1125–
1136.
46. Celik, L., J. D. D. Lund, and B. Schiøtt. 2007. Conformational
dynamics of the estrogen receptor a: molecular dynamics simula-
tions of the inﬂuence of binding site structure on protein dynamics.
Biochemistry. 46:1743–1758.
47. Zoete, V., M. Meuwly, and M. Karplus. 2005. Study of the insulin
dimerization: binding free energy calculations and per-residue free
energy decomposition. Proteins. 61:79–93.
48. Fujiwara, S., and T. Amisaki. 2006. Molecular dynamics study of
conformational changes in human serum albumin by binding of fatty
acids. Proteins. 64:730–739.
49. Masukawa, K. M., P. A. Kollman, and I. D. Kuntz. 2003. Investigation
of neuraminidase-substrate recognition using molecular dynamics and
free energy calculations. J. Med. Chem. 46:5628–5637.
50. Pedersen, A. O., B. Honore´, and R. Brodersen. 1990. Thermodynamic
parameters for binding of fatty acids to human serum albumin. Eur. J.
Biochem. 190:497–502.
51. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD—visual molec-
ular dynamics. J. Mol. Graph. 14:33–38.
MM-PBSA for Seven FA Binding Sites on HSA 103
Biophysical Journal 94(1) 95–103
